A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses
- Author
- CAMERON, David1 ; CASEY, Michelle2 ; CHAN, Arlene11 ; CAMPONE, Mario12 ; VIENS, Patrice13 ; DAVIDSON, Neville14 ; GORBOUNOVA, Veira15 ; RAATS, Johannes Isaac16 ; SKARLOS, Dimosthenis17 ; NEWSTAT, Beth2 ; ROYCHOWDHURY, Debasish3 ; PAOLETTI, Paolo2 ; PRESS, Michael3 ; OLIVA, Cristina2 ; RUBIN, Stephen2 ; STEIN, Steven2 ; GEYER, Charles E18 ; LINDQUIST, Deborah4 ; PIENKOWSKI, Tadeusz5 ; GILLES ROMIEU, C6 ; CHAN, Stephen7 ; JAGIELLO-GRUSZFELD, Agnieszka8 ; KAUFMAN, Bella9 ; CROWN, John10
[1] University of Leeds, Leeds, United Kingdom
[2] GlaxoSmithKline, Collegeville, PA, United States
[3] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States
[4] US Oncology, Houston, TX, United States
[5] Breast Cancer and Reconstruction Surgery Department, Centrum Onkologii Klinika Nowotworów Piersi i Chirurgii, Warsaw, Poland
[6] Département Oncologie, CRLCC Val d'Aurelle, Montpellier, France
[7] Department of Clinical Oncology, Nottingham University Hospitals, Nottingham, United Kingdom
[8] Chemotherapy Department, ZOZ MSWiA, Olsztyn, Poland
[9] Oncology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel
[10] Irish Clinical Oncology Research Group, Dublin, Ireland
[11] Mount Medical Centre, Mount Hospital, Perth, Australia
[12] Oncology Department, Centre René Gauducheau, Gauducheau, Saint Herblain, France
[13] Institut Paoli Calmette, Université de la Méditerranée, Marseille, France
[14] Broomfield Hospital, Chelmsford, United Kingdom
[15] Russian National Cancer Research Center, Moscow, Russian Federation
[16] Panorama Medical Center, Cape Town, South Africa
[17] 2nd Medical Oncology Department of Errikos Dunan Hospital, Errikos Dynan Hospital-B, Athens, Greece
[18] Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA, United States - Source
Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, 11 p ; ref : 19 ref
- CODEN
- BCTRD6
- ISSN
- 0167-6806
- Scientific domain
- Medical oncology; Obstetrics, gynecology, andrology; Pharmacology drugs
- Publisher
- Springer, Dordrecht
- Publication country
- Netherlands
- Document type
- Article
- Language
- Russian
- Author keyword
- Advanced breast cancer . Lapatinib Capecitabine Dual tyrosine kinase inhibitor . Phase III . Biomarker HER2-positive Metastatic breast cancer
- Keyword (fr)
- Adulte Anticancéreux Association médicamenteuse Cancer du sein Capécitabine Efficacité traitement Etude comparative Femme Gène erbB2 Inhibiteur de la tyrosine kinase Lapatinib Marqueur biologique Métastase Promédicament Protooncogène Randomisation Stade avancé Trastuzumab Anti-HER2 Anticorps monoclonal Cancer Dérivé de la fluoropyrimidine Homme Pathologie de la glande mammaire Pathologie du sein Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Adult Antineoplastic agent Drug combination Breast cancer Capecitabine Treatment efficiency Comparative study Woman erbB2 Gene Tyrosine kinase inhibitor Lapatinib Biological marker Metastasis Prodrug Protooncogene Randomization Advanced stage Trastuzumab Monoclonal antibody Cancer Fluoropyrimidine derivatives Human Mammary gland diseases Breast disease Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Adulto Anticanceroso Asociación medicamentosa Cáncer del pecho Capecitabina Eficacia tratamiento Estudio comparativo Mujer Gen erbB2 Inhibidor tyrosine kinase Lapatinib Marcador biológico Metástasis Promedicamento Protooncogen Aleatorización Estadio avanzado Trastuzumab Anticuerpo monoclonal Cáncer Fluoropirimidina derivado Hombre Glándula mamaria patología Seno patología Pirimidina nucleósido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20901947
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s10549-007-9885-0 
https://dx.doi.org/10.1007/s10549-007-9885-0
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-007-9885-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"533\";s:8:\"\u0000*\u0000epage\";s:3:\"543\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CAMERON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"CASEY, Michelle\";i:1;s:12:\"CHAN, Arlene\";i:2;s:14:\"CAMPONE, Mario\";i:3;s:14:\"VIENS, Patrice\";i:4;s:17:\"DAVIDSON, Neville\";i:5;s:17:\"GORBOUNOVA, Veira\";i:6;s:21:\"RAATS, Johannes Isaac\";i:7;s:20:\"SKARLOS, Dimosthenis\";i:8;s:13:\"NEWSTAT, Beth\";i:9;s:22:\"ROYCHOWDHURY, Debasish\";i:10;s:15:\"PAOLETTI, Paolo\";i:11;s:14:\"PRESS, Michael\";i:12;s:15:\"OLIVA, Cristina\";i:13;s:14:\"RUBIN, Stephen\";i:14;s:13:\"STEIN, Steven\";i:15;s:16:\"GEYER, Charles E\";i:16;s:18:\"LINDQUIST, Deborah\";i:17;s:19:\"PIENKOWSKI, Tadeusz\";i:18;s:16:\"GILLES ROMIEU, C\";i:19;s:13:\"CHAN, Stephen\";i:20;s:29:\"JAGIELLO-GRUSZFELD, Agnieszka\";i:21;s:14:\"KAUFMAN, Bella\";i:22;s:11:\"CROWN, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-007-9885-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"533\";s:8:\"\u0000*\u0000epage\";s:3:\"543\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CAMERON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"CASEY, Michelle\";i:1;s:12:\"CHAN, Arlene\";i:2;s:14:\"CAMPONE, Mario\";i:3;s:14:\"VIENS, Patrice\";i:4;s:17:\"DAVIDSON, Neville\";i:5;s:17:\"GORBOUNOVA, Veira\";i:6;s:21:\"RAATS, Johannes Isaac\";i:7;s:20:\"SKARLOS, Dimosthenis\";i:8;s:13:\"NEWSTAT, Beth\";i:9;s:22:\"ROYCHOWDHURY, Debasish\";i:10;s:15:\"PAOLETTI, Paolo\";i:11;s:14:\"PRESS, Michael\";i:12;s:15:\"OLIVA, Cristina\";i:13;s:14:\"RUBIN, Stephen\";i:14;s:13:\"STEIN, Steven\";i:15;s:16:\"GEYER, Charles E\";i:16;s:18:\"LINDQUIST, Deborah\";i:17;s:19:\"PIENKOWSKI, Tadeusz\";i:18;s:16:\"GILLES ROMIEU, C\";i:19;s:13:\"CHAN, Stephen\";i:20;s:29:\"JAGIELLO-GRUSZFELD, Agnieszka\";i:21;s:14:\"KAUFMAN, Bella\";i:22;s:11:\"CROWN, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-007-9885-0\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-007-9885-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"533\";s:8:\"\u0000*\u0000epage\";s:3:\"543\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CAMERON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"CASEY, Michelle\";i:1;s:12:\"CHAN, Arlene\";i:2;s:14:\"CAMPONE, Mario\";i:3;s:14:\"VIENS, Patrice\";i:4;s:17:\"DAVIDSON, Neville\";i:5;s:17:\"GORBOUNOVA, Veira\";i:6;s:21:\"RAATS, Johannes Isaac\";i:7;s:20:\"SKARLOS, Dimosthenis\";i:8;s:13:\"NEWSTAT, Beth\";i:9;s:22:\"ROYCHOWDHURY, Debasish\";i:10;s:15:\"PAOLETTI, Paolo\";i:11;s:14:\"PRESS, Michael\";i:12;s:15:\"OLIVA, Cristina\";i:13;s:14:\"RUBIN, Stephen\";i:14;s:13:\"STEIN, Steven\";i:15;s:16:\"GEYER, Charles E\";i:16;s:18:\"LINDQUIST, Deborah\";i:17;s:19:\"PIENKOWSKI, Tadeusz\";i:18;s:16:\"GILLES ROMIEU, C\";i:19;s:13:\"CHAN, Stephen\";i:20;s:29:\"JAGIELLO-GRUSZFELD, Agnieszka\";i:21;s:14:\"KAUFMAN, Bella\";i:22;s:11:\"CROWN, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-007-9885-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"533\";s:8:\"\u0000*\u0000epage\";s:3:\"543\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CAMERON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"CASEY, Michelle\";i:1;s:12:\"CHAN, Arlene\";i:2;s:14:\"CAMPONE, Mario\";i:3;s:14:\"VIENS, Patrice\";i:4;s:17:\"DAVIDSON, Neville\";i:5;s:17:\"GORBOUNOVA, Veira\";i:6;s:21:\"RAATS, Johannes Isaac\";i:7;s:20:\"SKARLOS, Dimosthenis\";i:8;s:13:\"NEWSTAT, Beth\";i:9;s:22:\"ROYCHOWDHURY, Debasish\";i:10;s:15:\"PAOLETTI, Paolo\";i:11;s:14:\"PRESS, Michael\";i:12;s:15:\"OLIVA, Cristina\";i:13;s:14:\"RUBIN, Stephen\";i:14;s:13:\"STEIN, Steven\";i:15;s:16:\"GEYER, Charles E\";i:16;s:18:\"LINDQUIST, Deborah\";i:17;s:19:\"PIENKOWSKI, Tadeusz\";i:18;s:16:\"GILLES ROMIEU, C\";i:19;s:13:\"CHAN, Stephen\";i:20;s:29:\"JAGIELLO-GRUSZFELD, Agnieszka\";i:21;s:14:\"KAUFMAN, Bella\";i:22;s:11:\"CROWN, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-007-9885-0\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"533\";s:8:\"\u0000*\u0000epage\";s:3:\"543\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"CAMERON\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"CASEY, Michelle\";i:1;s:12:\"CHAN, Arlene\";i:2;s:14:\"CAMPONE, Mario\";i:3;s:14:\"VIENS, Patrice\";i:4;s:17:\"DAVIDSON, Neville\";i:5;s:17:\"GORBOUNOVA, Veira\";i:6;s:21:\"RAATS, Johannes Isaac\";i:7;s:20:\"SKARLOS, Dimosthenis\";i:8;s:13:\"NEWSTAT, Beth\";i:9;s:22:\"ROYCHOWDHURY, Debasish\";i:10;s:15:\"PAOLETTI, Paolo\";i:11;s:14:\"PRESS, Michael\";i:12;s:15:\"OLIVA, Cristina\";i:13;s:14:\"RUBIN, Stephen\";i:14;s:13:\"STEIN, Steven\";i:15;s:16:\"GEYER, Charles E\";i:16;s:18:\"LINDQUIST, Deborah\";i:17;s:19:\"PIENKOWSKI, Tadeusz\";i:18;s:16:\"GILLES ROMIEU, C\";i:19;s:13:\"CHAN, Stephen\";i:20;s:29:\"JAGIELLO-GRUSZFELD, Agnieszka\";i:21;s:14:\"KAUFMAN, Bella\";i:22;s:11:\"CROWN, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
